Meeting
2013 ASCO Annual Meeting
Independent characterization by duel staining of progesterone receptor (PR) and estrogen receptor (ER) in breast cancer (BC).
Authors
Alexander A. Zukiwski
ARNO Therapeutics, Flemington, NJ
Alexander A. Zukiwski , Jean-Michel Caillaud , Jacques Bosq , Suzanne A. W. Fuqua , Carol A. Lange , Joyce O'Shaughnessy , Erard M. Gilles , Jacques Bonneterre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 31, 2013 (suppl; abstr 596)
DOI
10.1200/jco.2013.31.15_suppl.596
Abstract #
596
Poster Bd #
8C
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Determination of the activated form of the progesterone receptor (PR) in endometrial cancer (EC).
First Author: Dinny Graham
Poster
2022 ASCO Annual Meeting
ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC).
First Author: Qiang Zhang
Poster
2021 ASCO Annual Meeting
Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
First Author: Grace Wei
Poster
2021 ASCO Annual Meeting
Trends in breast cancer incidence among young women aged 20 to 49 years in the United States.
First Author: Shuai Xu